Sandoz Group AG (Sandoz Group AG) Gross-Profit-to-Asset % : 98.72% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sandoz Group AG's annualized Gross Profit for the quarter that ended in Dec. 2023 was $18,256 Mil. Sandoz Group AG's average Total Assets over the quarter that ended in Dec. 2023 was $18,494 Mil. Therefore, Sandoz Group AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 98.72%.

Sandoz Group AG Gross-Profit-to-Asset % Historical Data

The historical data trend for Sandoz Group AG's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Gross-Profit-to-Asset % Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Gross-Profit-to-Asset %

24.94

24.68

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Gross-Profit-to-Asset %	99.74	98.72

Competitive Comparison of Sandoz Group AG's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Gross-Profit-to-Asset % falls into.

Sandoz Group AG Gross-Profit-to-Asset % Calculation

Sandoz Group AG's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4564	/	( (17557	+	19430)	/ 2 )
	=	4564	/	18493.5
	=	24.68 %

Sandoz Group AG's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	18256	/	( (17557	+	19430)	/ 2 )
	=	18256	/	18493.5
	=	98.72 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sandoz Group AG Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024